- Home
- GNTA vs CGTX Comparison
GNTA vs CGTX Comparison
Compare GNTA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- CGTX
- Stock Information
- Founded
- GNTA 2014
- CGTX 2007
- Country
- GNTA Italy
- CGTX United States
- Employees
- GNTA N/A
- CGTX N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- CGTX Health Care
- Exchange
- GNTA Nasdaq
- CGTX Nasdaq
- Market Cap
- GNTA 67.4M
- CGTX 79.3M
- IPO Year
- GNTA 2021
- CGTX 2021
- Fundamental
- Price
- GNTA $5.34
- CGTX $0.55
- Analyst Decision
- GNTA Strong Buy
- CGTX Buy
- Analyst Count
- GNTA 1
- CGTX 6
- Target Price
- GNTA $25.00
- CGTX $8.00
- AVG Volume (30 Days)
- GNTA 28.4K
- CGTX 588.8K
- Earning Date
- GNTA 01-01-0001
- CGTX 11-08-2024
- Dividend Yield
- GNTA N/A
- CGTX N/A
- EPS Growth
- GNTA N/A
- CGTX N/A
- EPS
- GNTA N/A
- CGTX N/A
- Revenue
- GNTA N/A
- CGTX N/A
- Revenue This Year
- GNTA N/A
- CGTX N/A
- Revenue Next Year
- GNTA N/A
- CGTX N/A
- P/E Ratio
- GNTA N/A
- CGTX N/A
- Revenue Growth
- GNTA N/A
- CGTX N/A
- 52 Week Low
- GNTA $2.20
- CGTX $0.34
- 52 Week High
- GNTA $7.28
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- GNTA 56.89
- CGTX 54.28
- Support Level
- GNTA $4.89
- CGTX $0.50
- Resistance Level
- GNTA $6.20
- CGTX $0.64
- Average True Range (ATR)
- GNTA 0.70
- CGTX 0.07
- MACD
- GNTA -0.06
- CGTX 0.02
- Stochastic Oscillator
- GNTA 37.32
- CGTX 67.74
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.